Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ADMA

Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits

ADMA stock plummeted Thursday after the biotech company slightly missed the Street's first-quarter expectations.

Investors Business Daily

3 Mid-Cap Medical Stocks Outperforming the Market

3 Mid-Cap Medical Stocks Outperforming the Market

Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.

Stock Market Today: Dow Jones Up But Nvidia Falls On New China Threat; Cathie Wood Loads Up On This Stock Amid 76% Dive (Live Coverage)

Stock Market Today: Dow Jones Up But Nvidia Falls On New China Threat; Cathie Wood Loads Up On This Stock Amid 76% Dive (Live Coverage)

The Dow Jones rose on the stock market today. Treasury Secretary Bessent spoke out on China. Some Warren Buffett stocks are near entries.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

IBD 50's Top Seed, ADMA, Just Rocketed On A New FDA Approval

ADMA stock rocketed Monday after the Food and Drug Administration approved its new immunoglobulin production process.

Investors Business Daily

Dow Jones Futures Jump On Trump's China, Powell Comments; Tesla Rises On Bullish Elon Musk

Futures rose as President Trump said China tariffs will fall "substantially" and won't fire Fed chief Powell. Stocks boomed Tuesday on Treasury Secretary Scott Bessent. Tesla earnings fell with Elon Musk bullish.

Investors Business Daily

How IBD Stock Of The Day ADMA Biologics Shrugged Off Accounting Debacle For A Bullish Comeback

ADMA Biologics is Thursday's IBD Stock Of The Day. After an accounting debacle hammered shares in 2024, ADMA stock is making a comeback.

Investors Business Daily

ADMA Stock Builds A Base As Profits Continue To Soar

This biopharmaceutical firm specializes in treatments to prevent and treat infectious diseases.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

There May Still Be Time to Get in on These 3 Trending Biotechs

There May Still Be Time to Get in on These 3 Trending Biotechs

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investors Business Daily

Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge

Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge

ADMA stock hit a new buy point in recent weeks after recovering from an unexpected plunge that sent shares below a key level.

Investors Business Daily

ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle

ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle

ADMA stock rocketed Friday after the biotech company inked a deal with KPMG as its new independent registered public accounting firm.

Investors Business Daily

IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns

IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns

ADMA stock plummeted Thursday after the company's auditor unexpectedly resigned. But ADMA Biologics kept its guidance for this year and next.

Investors Business Daily

The Real Best Stock Of The Year Isn't In The S&P 500 Yet

The Real Best Stock Of The Year Isn't In The S&P 500 Yet

If you're like most investors — you assume AI giant Nvidia is the best stock of the year. But 2024's major champ isn't even in the S&P 500.

Investors Business Daily

Why ADMA Biologics Shares Are Rising Today

Why ADMA Biologics Shares Are Rising Today

ADMA Biologics Inc (NASDAQ: ADMA) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration approval for its sixth plasma collection center.

Get all your
news in one place.

100’s of premium titles.
One news app.

Looking Into ADMA Biologics's Return On Capital Employed

Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter.

Recap: ADMA Biologics Q1 Earnings

ADMA Biologics (NASDAQ:ADMA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings ADMA Biologics missed estimated earnings by 25.0%, reporting an EPS of $-0.1 versus an estimate of $-0.08.

Earnings Outlook For ADMA Biologics

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.08.

ADMA Biologics's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, ADMA Biologics's (NASDAQ:ADMA) reported sales totaled $26.38 million. Despite a 6.0% increase in earnings, the company posted a loss of $16.65 million.

Get all your
news in one place.

100’s of premium titles.
One news app.

ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing

ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022.

ADMA Biologics's Earnings Outlook

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.09.

ADMA Biologics Shares Gain As Interim Q4 Sales Beat Expectation

ADMA Biologics Inc (NASDAQ: ADMA) expects

The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

People

129,388 stories

Robert F. Kennedy Jr

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

289,447 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play